Alto Neuroscience (ANRO) Debt to Equity (2023 - 2026)
Alto Neuroscience has reported Debt to Equity over the past 4 years, most recently at $0.07 for Q1 2026.
- Quarterly results put Debt to Equity at $0.07 for Q1 2026, down 54.08% from a year ago — trailing twelve months through Mar 2026 was $0.07 (down 54.08% YoY), and the annual figure for FY2025 was $0.11, up 63.76%.
- Debt to Equity reached $0.07 in Q1 2026 per ANRO's latest filing, down from $0.11 in the prior quarter.
- Across five years, Debt to Equity topped out at $0.18 in Q3 2025 and bottomed at -$0.14 in Q4 2023.
- Median Debt to Equity over the past 4 years was $0.07 (2026), compared with a mean of $0.08.
- The largest annual shift saw Debt to Equity skyrocketed 195.94% in 2025 before it crashed 54.08% in 2026.
- Over 4 years, Debt to Equity stood at -$0.14 in 2023, then skyrocketed by 149.21% to $0.07 in 2024, then skyrocketed by 63.76% to $0.11 in 2025, then plummeted by 40.62% to $0.07 in 2026.
- Business Quant data shows Debt to Equity for ANRO at $0.07 in Q1 2026, $0.11 in Q4 2025, and $0.18 in Q3 2025.